A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Xiao-Jiang Sun, Qing-Hua Deng, Xin-Min Yu, Yong-Lin Ji, Yuan-Da Zheng, Hao Jiang, Ya-Ping Xu, Sheng-Lin Ma, Xiao-Jiang Sun, Qing-Hua Deng, Xin-Min Yu, Yong-Lin Ji, Yuan-Da Zheng, Hao Jiang, Ya-Ping Xu, Sheng-Lin Ma

Abstract

Background: Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in different human cancers. This study assessed the efficacy of endostatin combined with concurrent chemoradiotherapy of non-small cell lung cancer (NSCLC).

Methods: Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. Patients were then treated with 7.5 mg/m(2) endostatin for 14 days, 150 mg/m(2) paclitaxel, and 5 mg/mL/min carboplatin every 3 weeks for 2 cycles as the consolidation treatment. The objective response rate was recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria.

Results: Six patients were unable to complete the consolidation treatment (4 pulmonary toxicity, 1 tracheoesophageal fistulae, and 1 progressive disease). Seventeen patients were included for data analysis. Specifically, one (5.9%) patient had a complete response and 12 (70.6%) had a partial response, whereas two patients had stable disease and the other two had disease progression. The overall response rate was 76% (95% confidence interval [CI], 51%-97%). The median progression-free survival was 10 months (95% CI, 7.6-12.3 months), and the median overall survival was 14 months (95% CI, 10.7-17.2 months). Early 10 patients who completed the treatment regimen showed that four patients experienced grade III pulmonary toxicity a few months after chemoradiotherapy, leading to the early closure of the trial according to the study design.

Conclusions: The result of concurrent endostatin treatment with chemoradiotherapy in locally advanced unresectable NSCLC did not meet the goal per study design with unacceptable toxicity. The real impact of endostatin as the first-line treatment combined with chemoradiotherapy on the survival of NSCLC patients remains to be determined. (NCT 01158144).

Trial registration: ClinicalTrials.gov NCT01158144.

Keywords: Clinical trial; Concurrent chemoradiotherapy; Endostatin; NSCLC.

Figures

Fig. 1
Fig. 1
Treatment schedules of the patients
Fig. 2
Fig. 2
Kaplan–Meier survival curves of progression-free survival and overall survival of patients. The median progression-free survival was 10 months (95 % CI, 7.6–12.3 months), and the median overall survival was 14 months (95 % CI, 10.7–17.2 months)

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.
    1. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–2699.
    1. Curran WJ, Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–1460. doi: 10.1093/jnci/djr325.
    1. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442–447. doi: 10.1126/science.2432664.
    1. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect. 1996;92:65–82.
    1. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(10):2705–2711.
    1. Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(6):1104–1109. doi: 10.1097/JTO.0b013e3182166b6b.
    1. Zhao X, Mei K, Cai X, Chen J, Yu J, Zhou C, et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs. 2012;30(3):1144–1149. doi: 10.1007/s10637-011-9631-7.
    1. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, et al. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 2007;67(3):870–878. doi: 10.1016/j.ijrobp.2006.10.030.
    1. Luo X, Slater JM, Gridley DS. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int J Radiat Oncol Biol Phys. 2005;63(2):553–564. doi: 10.1016/j.ijrobp.2005.01.038.
    1. Englert S, Kieser M. Optimal adaptive two-stage designs for phase II cancer clinical trials. Biom J. 2013;55(6):955–968. doi: 10.1002/bimj.201200220.
    1. Wang L, Wu S, Ou G, Bi N, Li W, Ren H, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77(1):89–96. doi: 10.1016/j.lungcan.2012.02.011.
    1. Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, et al. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer. 2001;94(3):420–428. doi: 10.1002/ijc.1471.
    1. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004;10(16):5361–5366. doi: 10.1158/1078-0432.CCR-04-0443.
    1. Ni Q, Ji H, Zhao Z, Fan X, Xu C. Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol. 2009;614(1–3):1–6. doi: 10.1016/j.ejphar.2009.04.032.
    1. Patton JF, Spigel DR, Greco FA, Liggett WH, Zubkus LD, Baskette M, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol. 2006;24(385a):7085).
    1. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol Off J Am Soc Clin. Oncol. 2010;28(1):43–48. doi: 10.1200/JCO.2009.24.7353.
    1. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004;22(21):4341–4350. doi: 10.1200/JCO.2004.03.022.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere